ASCO Audio Journal of Oncology in Advance – July 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007
0
Volker Diehl
George Canellos
Hodgkin’s Disease: 10-Year Results Show Further Benefit From Escalated BEACOPP Therapy
REFERENCE: Abstract 8015, ASCO Annual Meeting Chicago June 1-5, 2007
VOLKER DIEHL, University of Cologne
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Long-term results presented at the ASCO Annual Meeting have given further support to the use of an escalated BEACOPP regimen in patients with Hodgkin’s disease. Volker Diehl, of the University of Cologne, discussed his latest data with George Canellos, of the Dana-Farber Cancer Institute in Boston, and Peter Goodwin.
VOLKER DIEHL, University of Cologne
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Long-term results presented at the ASCO Annual Meeting have given further support to the use of an escalated BEACOPP regimen in patients with Hodgkin’s disease. Volker Diehl, of the University of Cologne, discussed his latest data with George Canellos, of the Dana-Farber Cancer Institute in Boston, and Peter Goodwin.
Sandra Horning
Less Radiation Is Significantly Better for Patients With Favorable Hodgkin’s Disease
REFERENCE: Abstract 8014, ASCO Annual Meeting Chicago June 1-5, 2007
SANDRA HORNING, Stanford University
Less aggressive radiotherapy when combined with chemotherapy has proven superior to the use of extended field radiotherapy for patients with favorable prognosis Hodgkin’s disease. This finding from long-term follow-up of mature data from a Stanford University study was presented at the 2007 ASCO Annual Meeting in Chicago. After her talk in the lymphoma session, Sandra Horning talked with Sarah Maxwell about her group’s latest results.
SANDRA HORNING, Stanford University
Less aggressive radiotherapy when combined with chemotherapy has proven superior to the use of extended field radiotherapy for patients with favorable prognosis Hodgkin’s disease. This finding from long-term follow-up of mature data from a Stanford University study was presented at the 2007 ASCO Annual Meeting in Chicago. After her talk in the lymphoma session, Sandra Horning talked with Sarah Maxwell about her group’s latest results.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Share
